GEV.US

1,062.39

-1.55%↓

GE

285.83

+1.92%↑

RTX

174.1

-1.22%↓

BA

224.24

+0.26%↑

UNP

263.24

-0.56%↓

GEV.US

1,062.39

-1.55%↓

GE

285.83

+1.92%↑

RTX

174.1

-1.22%↓

BA

224.24

+0.26%↑

UNP

263.24

-0.56%↓

GEV.US

1,062.39

-1.55%↓

GE

285.83

+1.92%↑

RTX

174.1

-1.22%↓

BA

224.24

+0.26%↑

UNP

263.24

-0.56%↓

GEV.US

1,062.39

-1.55%↓

GE

285.83

+1.92%↑

RTX

174.1

-1.22%↓

BA

224.24

+0.26%↑

UNP

263.24

-0.56%↓

GEV.US

1,062.39

-1.55%↓

GE

285.83

+1.92%↑

RTX

174.1

-1.22%↓

BA

224.24

+0.26%↑

UNP

263.24

-0.56%↓

Начало・Списък с акции・Ocugen Inc

Search

Ocugen Inc

Отворен

1.79 3.47

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.78

Максимум

1.79

Ключови измерители
By Trading Economics
Приходи	2.3M -18M
Продажби	-1.9M -193K
Марж на печалбата	9,174.093
Служители	116
EBITDA	1.5M -16M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+566.49% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-78M 557M
Предишно отваряне	-1.68
Предишно затваряне	1.79

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 22:17 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4.05.2026 г., 23:47 ч. UTC

Печалби

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4.05.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Steady Amid Likely Technical Recovery -- Market Talk

4.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Regis: Jim Beyer To Be Chief Executive of Combined Company

4.05.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Shareholders to Own About 51% of Combined Company

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Board Unanimously Endorsed, Supported Deal

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Deal Unanimously Recommended by Vault Board

4.05.2026 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources to Acquire All Ordinary Shares in Vault

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources, Vault Minerals Agree to Merger of Equals

4.05.2026 г., 22:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4.05.2026 г., 22:26 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4.05.2026 г., 22:02 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4.05.2026 г., 22:00 ч. UTC

Пазарно говорене

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4.05.2026 г., 21:52 ч. UTC

Печалби

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Some Sectors More Affected Than Others>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4.05.2026 г., 21:49 ч. UTC

Печалби

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4.05.2026 г., 21:43 ч. UTC

Печалби

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4.05.2026 г., 21:41 ч. UTC

Печалби

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4.05.2026 г., 21:40 ч. UTC

Печалби

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

566.49% нагоре

12-месечна прогноза

Среден 12.33 USD 566.49%

Висок 22 USD

Нисък 8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Според 6 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Други акции от сектора

GEV.US

GE Vernova LLC

1,062.39

GE

General Electric Co.

285.83

RTX

Raytheon Technologies Corp.

174.1

BA

Boeing Co.

224.24

UNP

Union Pacific Corp

263.24

Live chat